Sugi Predict

Sugi Predict / Compounds / SCHEMBL146025

SCHEMBL146025

SCHEMBL146025

O=c1[nH]c(F)nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 9/20 0.61
▸ PARP1 P09874 5/20 0.61
▸ QTRT1 Q9BXR0 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ TNKS O95271 7/20 0.60
▸ PARP2 Q9UGN5 2/20 0.60
▸ KMT2A Q03164 1/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ TUBB4A P04350 1/20 0.53
▸ TUBB P07437 1/20 0.53
▸ TUBA3C P0DPH7 1/20 0.53
▸ TUBA1B P68363 1/20 0.53
▸ TUBA4A P68366 1/20 0.53
▸ TUBB4B P68371 1/20 0.53
▸ TUBB3 Q13509 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551160 1.00 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS
Ethoxycarbonyl Group SCHEMBL28784396 0.82 TNKS2 (0.51) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL6695759 0.79 TNKS2 (0.81) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL31079885 0.77 TUBB4A (0.57) TNKS2PARP1TNKSPARP2TUBB4A
SCHEMBL1772523 0.76 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL103994 0.76 QTRT1 (1.00) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL894736 0.76 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL22021640 0.76 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL22807316 0.76 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS
SCHEMBL31070302 0.76 TNKS2 (0.61) TNKS2PARP1QTRT1PKMTNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108440407-A A kind of preparation method for the chloro- 6- nitros -7- fluorine quinoline of 4- that Vilsmeier reagents participate in 郭丽 2018-08-24 — — CN claimed
CN-106660994-A Phosphatidylinositol 3-kinase inhibitors 吉利德科学公司 2017-05-10 — — CN claimed
EP-3154962-A2 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Gilead Sciences, Inc. (US) 2017-04-19 — — EP claimed
CN-106573922-A Phosphatidylinositol 3-kinase inhibitors 吉利德科学公司 2017-04-19 — — CN claimed
CN-103304492-B The synthetic method of a kind of EGFR inhibitor Dacomitinib HUNAN OUYA BIOLOGICAL CO., LTD. (CN) 2015-12-23 — — CN claimed
WO-2015191754-A2 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 — — WO claimed
CN-104662006-A Quinazolinone derivatives as PARP inhibitors MERCK PATENT GMBH 2015-05-27 — — CN claimed
US-20240208944-A1 Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition UNIV EMORY (US) 2024-06-27 — — US disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
US-20240101540-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY ABBVIE BIOTECHNOLOGY LTD (BM) 2024-03-28 — — US disclosed
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2023-01-19 — — US disclosed
CN-104744446-B Heteroaryl compound and its application in drug 广东东阳光药业有限公司 2019-06-25 — — CN disclosed
CN-109694357-A A kind of preparation method of high-purity afatinib intermediate 南京天越星生物技术有限公司 2019-04-30 — — CN disclosed
CN-102427813-A Novel anti-inflammatory agents RESVERLOGIX CORP 2012-04-25 — — CN disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 — — US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
CN-101341133-A Quinazoline derivatives, process for their preparation and their use as anti-cancer agents ASTRAZENECA AB (SE) 2009-01-07 — — CN disclosed
US-6306864-B1 CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA PFIZER INC. 2001-10-23 — — US disclosed
US-6294532-B1 TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. ZENECA LIMITED (GB) 2001-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TNKS2 504/4885PARP1 785/4885QTRT1 830/4885
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 TNKS2 17/4885PARP1 5/4885QTRT1 296/4885
US-20240208944-A1 Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition NOX1, NOX5, NOX3 TNKS2 854/4885PARP1 518/4885QTRT1 773/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TNKS2 504/4885PARP1 785/4885QTRT1 830/4885
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 TNKS2 17/4885PARP1 5/4885QTRT1 296/4885
US-20240101540-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY PARP14, PARP15, PARP16 TNKS2 17/4885PARP1 8/4885QTRT1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.